The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells …PR Newswire (press release)Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an av…
Indian-origin man fails to find burial place for wife's ashes – Times of India
|
Indian-origin man fails to find burial place for wife’s ashes
Times of India Mariasusai Andrews, an Indian Christian, couldn’t find a place for the burial of his late wife Nirmala’s ashes even after six months of her death. She died at the age of 51 after she developed lung cancer. The urn containing Nirmala’s ashes is still in … |
Archway mother struck down by mystery heart failure 'turns blue' in front of … – Islington Gazette
Islington Gazette |
Archway mother struck down by mystery heart failure ‘turns blue’ in front of …
Islington Gazette Recording a verdict of death by natural causes, the coroner said: “She died of cardiac dysrhythmia – heart failure – without any real explanation as to why. “She was a healthy lady with a normal heart and nothing was identified which could cause her … |
Roche Holding Ltd. (ADR) (RHHBY): Roche: Impact Of Rituxan Patent Expiration … – Seeking Alpha
|
Roche Holding Ltd. (ADR) (RHHBY): Roche: Impact Of Rituxan Patent Expiration …
Seeking Alpha (click to enlarge) Rituxan (rituximab), MabThera in Europe, is a monoclonal antibody against B-lymphocytes CD20 surface protein used to treat lymphomas, leukemias, transplant rejection and rheumatoid arthritis. Novartis’ Sandoz generics division is on … |
STENTYS to Present First Results of Sirolimus-Eluting Self-Apposing(R) Stent … – Wall Street Journal
|
STENTYS to Present First Results of Sirolimus-Eluting Self-Apposing(R) Stent …
Wall Street Journal STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world’s first and only Self-Apposing(R) Stent to treat acute myocardial infarction (AMI), today announced that the 4-month results of the APPOSITION IV trial will be … |
Heart failure operation first for UK – Labmate Online
BBC NewsHeart failure operation first for UKLabmate OnlineThe first operation aimed at improving the way in which failing hearts function has been performed in the UK. The pioneering procedure treats hearts while they are still beating, making the expe…
STENTYS to Present First Results of Sirolimus-eluting Self-Apposing® Stent at … – 4-traders (press release)
|
STENTYS to Present First Results of Sirolimus-eluting Self-Apposing® Stent at …
4-traders (press release) STENTYS (Paris:STNT) (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced that the 4-month results of the APPOSITION IV trial … |
The Most Widespread Environmental Carcinogen? The Air We Breathe – The Atlantic Cities
The New Indian ExpressThe Most Widespread Environmental Carcinogen? The Air We BreatheThe Atlantic CitiesSome 223,000 lung cancer deaths around the world in 2010 could be attributed to air pollution, according to the report. There is … IARC officials…
STENTYS to Present First Results of Sirolimus-Eluting Self-Apposing® Stent at … – Business Wire (press release)
|
STENTYS to Present First Results of Sirolimus-Eluting Self-Apposing® Stent at …
Business Wire (press release) PRINCETON, N.J. & PARIS–(BUSINESS WIRE)–STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced that the 4-month … |
Global and Chinese Monoclonal Antibody Industry Report, 2013 – GlobeNewswire (press release)
Global and Chinese Monoclonal Antibody Industry Report, 2013GlobeNewswire (press release)In 2011, the sales of six monoclonal antibody agents as Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab …